在固体瘤治疗中,T细胞参与的双特异性抗体的进展
1Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
International immunopharmacology
|July 6, 2024
概括
参与T细胞的双特异性抗体 (TCBs) 对癌症治疗有希望,但在固体瘤中面临挑战. 优化TCB结构,目标和组合可以提高疗效并克服毒性.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 参与T细胞的双特异性抗体 (TCBs) 将T细胞重定向以消除瘤细胞.
- TCB已被批准用于血液恶性瘤和一些固体瘤.
- 用TCB治疗固体瘤面临诸多挑战,包括毒性和瘤微环境.
研究的目的:
- 审查关于固体瘤TCBs的临床数据.
- 为突出TCB治疗固体瘤的挑战.
- 讨论TCB开发和应用的新兴策略.
主要方法:
- 对固体瘤TCBs的临床数据的审查.
- 对TCB策略的临床前和临床研究的分析.
- 讨论TCB结构优化,标选择和组合疗法.
主要成果:
- TCBs显示出治疗潜力,但在固体瘤中面临重大障碍.
- 在点外瘤毒性,细胞因子释放综合征 (CRS) 和T细胞功能障碍是关键的挑战.
- 新兴的策略提供了潜在的解决方案,以提高TCB的疗效.
结论:
- 进一步的研究和战略开发对于TCB在固体瘤中的成功应用至关重要.
- 优化TCB设计,目标选择和组合疗法是克服当前局限性的关键.
- 本综述为推进TCB从概念到癌症免疫疗法的临床使用提供了指导.
相关概念视频
01:27Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K